1. López-Medina C, Doblas A, Escudero-Contreras A, Collantes-Estévez E. Safe Treatment With Secukinumab in a Patient With Axial Spondyloarthritis and a History of a Leishmania donovani Infection. J Rheumatol 2023; 50: 1521-1522.
2.
Kurizky PS, Marianelli FF, Cesetti MV, et al. A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases. Rev Inst Med Trop Sao Paulo 2020; 62: e28.
3.
Scholl S, Schuster D, Technau-Hafsi K, et al. Case report: Cutaneous pseudolymphoma caused by a Leishmania infantum infection in a patient treated with anti-TNF antibody for plaque psoriasis. Front Med (Lausanne) 2022; 9: 1055703.
4.
Lupia T, Corcione S, Fornari V, et al. Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis. Trop Med Infect Dis 2022; 7: 319.
5.
Billings SD, Cotton J. Inflammatory dermatopathology. A pathologist’s survival guide. 2nd Edition. Springer, Cham 2016.
6.
Busam KJ. Dermatopathology. A Volume in a Series: Foundations in Diagnostic Pathology. Series Editor: Goldblum JR. 2nd Edition. Elsevier Saunders, Philadelphia 2014.
7.
Fernandez-Flores A. A new scenario in the immunohistochemical diagnosis of cutaneous leishmaniasis. J Cutan Pathol 2017; 44: 1051-1052.
8.
Sundharkrishnan L, North JP. Histopathologic features of cutaneous leishmaniasis and use of CD1a staining for amastigotes in Old World and New World leishmaniasis. J Cutan Pathol 2017; 44: 1005-1011.
9.
Ferrufino-Schmidt MC, Bravo F, Valencia BM, Llanos-Cuentas A, Boggild AK, LeBoit PE. Is CD1a useful for leishmaniasis diagnosis in the New World?. J Cutan Pathol 2019; 46: 90-92.
10.
DeCoste R, Walsh NM, Pasternak S. The EP3622 clone of CD1a in the diagnosis of cutaneous leishmaniasis. J Cutan Pathol 2020; 47: 666-667.
11.
Hammond AM, Kallis PJ, Sokumbi O, Auerbach J, Vincek V, Motaparthi K. The EP3662 clone of CD1a supports the diagnosis of New World cutaneous leishmaniasis. J Cutan Pathol 2021; 48: 1317-1320.
12.
Lopez-Trujillo E, Gonzàlez-Farré M, Pujol RM, et al. Diagnostic usefulness of immunohistochemical evaluation of CD1a antigen and polyclonal anti-leishmania antibodies in cutaneous leishmaniasis. Histol Histopathol 2021; 36: 567-576.
13.
Neumayr AL, Morizot G, Visser LG, et al. Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-a antagonists. Travel Med Infect Dis 2013; 11: 412-420.
14.
Bagalas V, Kioumis I, Argyropoulou P, Patakas D. Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 2007; 26: 1344-1345.
15.
Kritikos K, Haritatos E, Tsigkos S, et al. An atypical presentation of visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with infliximab. J Clin Rheumatol 2010; 16: 38-39.
16.
Moltó A, Mateo L, Lloveras N, Olivé A, Minguez S. Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. Joint Bone Spine 2010; 77: 271-273.
17.
Balato A, Balato N, Patruno C, Gallo L, Ayala F. Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab. Dermatology 2008; 217: 360-361.
18.
Nieto Gómez P, Casas Hidalgo I, Casas Hidalgo MP, Álvarez Sánchez R, Rodríguez Delgado A, Cabeza-Barrera J. Cutaneous leishmaniasis associated with TNF-a blockers: a case report. Eur J Hosp Pharm 2019; 26: 233-234.
19.
Palacios-Diaz RD, Sahuquillo-Torralba A, Rocamora-Durán V, et al. Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF-a inhibitors. J Dtsch Dermatol Ges 2023; 21: 473-480.
20.
Glans H, Dotevall L, Van der Auwera G, et al. Treatment outcome of imported cutaneous leishmaniasis among travelers and migrants infected with Leishmania major and Leishmania tropica: a retrospective study in European centers 2013 to 2019. Int J Infect Dis 2022; 122: 375-381.
21.
Guarneri C, Bevelacqua V, Patterson JW, Tchernev G. Cutaneous and visceral leishmaniasis during anti-TNFa therapy. Wien Med Wochenschr 2017; 167: 78-82.
22.
Souza RM, Andrade HF Junior, Duarte MI, et al. Reactivation of cutaneous and mucocutaneous tegumentary leishmaniasis in rheumatoid arthritis patients: an emerging problem? Rev Inst Med Trop Sao Paulo 2017; 59: e6.
23.
Bosch-Nicolau P, Ubals M, Salvador F, et al. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression. PLoS Negl Trop Dis 2019; 13: e0007708.
24.
Hammarström H, Moreno J, Dotevall L, Calander AM. Leishmania infantum infection after visiting southern Spain in patients on biological treatment; an observational, longitudinal, cohort study. Travel Med Infect Dis 2023; 53: 102570.
